These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12118036)

  • 1. More concern about transfusion requirement when evaluating quality of life in anemic patients.
    Oliva EN; D'Angelo A; Martino B; Nobile F; Dimitrov BD; Perna A
    J Clin Oncol; 2002 Jul; 20(14):3182-3; author reply 3183-4. PubMed ID: 12118036
    [No Abstract]   [Full Text] [Related]  

  • 2. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue.
    Caocci G; Baccoli R; Ledda A; Littera R; La Nasa G
    Leuk Res; 2007 Feb; 31(2):249-52. PubMed ID: 16814382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
    Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
    Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.
    Tanasijevic AM; Revette A; Klepin HD; Zeidan A; Townsley D; DiNardo CD; Sebert M; DeZern AE; Stone RM; Magnavita ES; Chen R; Sekeres MA; Abel GA
    Leuk Lymphoma; 2020 Dec; 61(12):2900-2904. PubMed ID: 32667230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials.
    Mo A; McQuilten ZK; Wood EM; Weinkove R
    Intern Med J; 2017 Jun; 47(6):695-698. PubMed ID: 28580745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study.
    Ramos F; Pedro C; Tormo M; de Paz R; Font P; Luño E; Caballero M; Solano F; Almagro M; Xicoy B; Jiménez M
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26729645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
    Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
    Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes.
    Jansen AJ; Essink-Bot ML; Beckers EA; Hop WC; Schipperus MR; Van Rhenen DJ
    Br J Haematol; 2003 Apr; 121(2):270-4. PubMed ID: 12694248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
    Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
    Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and therapy of anemia in the elderly].
    Murai Y
    Nihon Naika Gakkai Zasshi; 1999 Jun; 88(6):1048-53. PubMed ID: 10465949
    [No Abstract]   [Full Text] [Related]  

  • 11. Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin.
    Thomas ML
    Med Oncol; 1998 Aug; 15 Suppl 1():S13-8. PubMed ID: 9785332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin therapy in cancer patients.
    Doweiko JP; Goldberg MA
    Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [There are no differences between non-diabetics and diabetics with respect to the effect of anaemia correction in chronic kidney disease].
    García López FJ
    Nefrologia; 2010; 30(2):258-9. PubMed ID: 20393624
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of cancer-related anemia on clinical and quality-of-life outcomes.
    Gillespie TW
    Clin J Oncol Nurs; 2002; 6(4):206-11. PubMed ID: 12087616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical evaluation of interleukin 3.
    Ganser A; Ottmann OG; Seipelt G; Hess U; Geissler G; Merget R; Falk S; Maurer A; Eder M; Hoelzer D
    Behring Inst Mitt; 1991 Dec; (90):50-61. PubMed ID: 1801691
    [No Abstract]   [Full Text] [Related]  

  • 16. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
    Ludwig H; Fritz E
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.
    Cella D; Zagari MJ; Vandoros C; Gagnon DD; Hurtz HJ; Nortier JW
    J Clin Oncol; 2003 Jan; 21(2):366-73. PubMed ID: 12525531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Permissive anemia].
    Shander A
    Zentralbl Chir; 2003 Jun; 128(6):468-71. PubMed ID: 12865951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
    Coyne DW
    Nephrol News Issues; 2013 Feb; 27(2):16, 18, 20. PubMed ID: 23469454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.